Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100167
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100167
Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy
Bomi Kim, Jaihwan Kim, Soomin Yang, Jinwoo Ahn, Kwangrok Jung, Jong-Chan Lee, Jin-Hyeok Hwang
Bomi Kim, Jaihwan Kim, Soomin Yang, Jinwoo Ahn, Kwangrok Jung, Jong-Chan Lee, Jin-Hyeok Hwang, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, South Korea
Author contributions: Kim B and Kim J contributed to conceptualization; Ahn J and Yang S curated the data; Lee JC conducted formal analysis; Jung K performed investigation and methodology; Hwang JH provided supervision; Kim B wrote the original draft; Kim J reviewed and edited the manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of the Seoul National University Bundang Hospital (No. B-2207-768-103).
Informed consent statement: Informed consent was waived by the Seoul National University Bundang Hospital Institutional Review Board.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The data used to support the findings are available from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jaihwan Kim, PhD, Professor, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Seongnam 13620, South Korea. drjaihwan@snu.ac.kr
Received: August 13, 2024
Revised: November 27, 2024
Accepted: December 10, 2024
Published online: February 15, 2025
Processing time: 157 Days and 17.6 Hours
Core Tip

Core Tip: This study retrospectively analyzed 141 patients with advanced pancreatic cancer treated between 2012 and 2021, who underwent first-line oxaliplatin or gemcitabine plus nab-paclitaxel, followed by third-line chemotherapy. The median overall survival was 19 months, with 15.3 weeks after third-line treatment. The study identified that patients with good performance status, carbohydrate antigen 19-9 < 1000 U/mL, second-line chemotherapy ≥ 19 weeks, and no peritoneal seeding before starting third-line treatment had better outcomes regardless of the third-line regimen. These findings suggest that such patients may benefit more from third-line chemotherapy in spite of unsatisfactory treatment results from all patients.